ArticleClinical breast cancer2026
Intraoperative and Perioperative Outcomes of Breast-Conserving Surgery After Neoadjuvant Systemic Therapy: A Retrospective Cohort Study.
Article in Clinical breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeNeoadjuvant chemotherapy (NAC), with or without immunotherapy (IO), is increasingly used in patients with breast cancer and may facilitate breast-conserving surgery (BCS). Because these therapies may alter physiologic reserve and perioperative care needs, we evaluated their associations with anesthetic management and postoperative recovery. PATIENTS AND
methodsThis retrospective cohort study included 374 patients with stage II-III breast cancer undergoing BCS at a high-volume ambulatory cancer center. Patients were categorized as receiving NAC, NAC + IO, or no neoadjuvant therapy. Primary outcomes were use of general anesthesia (GA) and postanesthesia care unit length of stay (PACU LOS). Multivariable models adjusted for age, body mass index, receptor subtype, tumor stage, and nodal status; the PACU LOS model additionally adjusted for surgery start time. Secondary outcomes included intraoperative propofol and opioid dosing per surgical hour and 30-day postoperative adverse events.
resultsNAC was associated with a 29% higher adjusted probability of GA use (95% confidence interval [CI], 15%-43%) and a 1.4-h longer PACU LOS (P = .001). Among patients receiving NAC, IO was associated with an 18% lower adjusted probability of GA use (95% CI, 3.1%-33%) and a 0.96-h shorter PACU LOS (P = .031). Intraoperative opioid requirements and 30-day postoperative adverse events did not differ meaningfully across treatment groups. Differences in propofol dosing were statistically significant but modest.
conclusionNeoadjuvant treatment exposure was associated with differences in anesthetic approach and postoperative recovery despite low complication rates. These findings support treatment-informed perioperative planning and multidisciplinary coordination for patients undergoing BCS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.